Monitor upcoming Phase 3 data for HLP003 (adjunctive MDD) and Phase 2 data for HLP004 (GAD) — hires signal preparation for potential commercialization but do not change near-term catalyst timeline.
Price Chart
Executive Summary
Helus Pharma (CYBIN Inc.) announced the appointment of Regina Donohue as Chief People Officer and Dr. Suresh Durgam to its Scientific Advisory Board. Both are former Intra-Cellular Therapies executives with experience scaling CNS drug development and commercialization. These are routine organizational hires with no material financial data or clinical catalysts provided — the filing carries no quantifiable revenue, earnings, or deal value and is not a market-moving event.
Key Facts
- Regina Donohue appointed Chief People Officer; previously Chief HR Officer at Intra-Cellular Therapies (acquired by Johnson & Johnson April 2025)
- Suresh Durgam, M.D., appointed to the Scientific Advisory Board; former EVP and Chief Medical Officer at Intra-Cellular, led CAPLYTA FDA approvals
- Helus Pharma is a clinical-stage company with HLP003 in Phase 3 for MDD (Breakthrough Therapy Designation) and HLP004 in Phase 2 for GAD
- No financial figures (revenue, EPS, deal value, dilution) were disclosed in the filing
Financial Impact
No material financial impact disclosed
Risk Factors
- Clinical-stage company with no approved products — reliance on regulatory and trial outcomes
- Forward-looking statements on commercialization are aspirational; no confirmed efficacy for NSA programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000061 |
| Document: cybininc-form6xk08x18x2026.htm | 0001833141-26-000061 |
| Document: 0001833141-26-000061-index-headers.html | 0001833141-26-000061 |
| Document: 0001833141-26-000061-index.html | 0001833141-26-000061 |
| Document: 0001833141-26-000061.txt | 0001833141-26-000061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers